Transformation of the Business Portfolio and Transformation Investments
First written in FY2017. 4 of 11 entries say "Advanced", first in FY2021. Latest entry: FY2026.
Sysmex moved to the "Worse" side of this theme in 2026.
The whole theme swung hardest in 2024: 2 of 14 companies on the "Worse" side.
3 other companies' latest entry also says "Reframed".
- FY2026ReframedAnnual report
「Under this medium-term management plan, we will prioritize the following 4 themes to turn our strengths into reliable growth opportunities: ① strengthening the competitiveness of the diagnostics business, ② promoting healthcare DX and data utilization by leveraging the strengths of the diagnostics business, ③ improving profitability through value chain reform, and ④ redesigning our financial and capital strategy.」
The policy of transforming our business portfolio was reorganized under the new medium-term management plan into 4 themes: the diagnostics business, healthcare DX and data, the value chain, and finance and capital. - FY2026-H1AdvancedAnnual report
「By acquiring the target business, including the highly competitive, high-quality BioMajesty, we will develop our partnerships with reagent manufacturers, expand opportunities for new collaborations worldwide and strengthen our product portfolio. In addition to expanding our business in the fields of biochemical and immunoassay testing alongside growth in the reagent business, we aim to meet solid global demand for testing by leveraging our strengths in providing a comprehensive product portfolio covering basic screening tests, as well as our sales and customer care capabilities.」
The acquisition of 日本電子’s medical equipment business made concrete our policy of strengthening the product portfolio, including BioMajesty, the biochemical and immunoassay testing businesses, the reagent business, and sales and customer care. - FY2025-H1AdvancedAnnual report
「June 2024: We began selling in Japan research-use reagents for measuring secreted proteins in cell culture media for regenerative cell medicine, namely the Research-use HISCL™ VEGF Reagent and Research-use HISCL™ PEDF Reagent (collectively, the Products).」
In the regenerative cell medicine field, we began selling research-use reagents for measuring secreted proteins in cell culture media and took concrete steps toward rolling out products aimed at automating and improving the efficiency of quality control testing for cell therapeutics. - FY2024RestatedAnnual report
「To achieve non-linear growth, we will newly add the MR (Medical Robot) business and regenerative cell therapy business, among others, and promote initiatives to expand our business domains.」
The policy to expand our business scope by adding the MR business and regenerative cell medicine business has been reiterated. - FY2024-Q3AdvancedAnnual report
「In the regenerative cell medicine field, we made 株式会社メガカリオン (Megakaryon) a consolidated subsidiary. Megakaryon has core technology for producing platelets from human iPS cells. By bringing Megakaryon into our Group, we will generate further synergies and accelerate the commercialization of high-quality, highly safe iPS cell-derived platelet products.」
As part of the policy to expand our business portfolio, we made Megakaryon, which has core technology for iPS cell-derived platelets, a consolidated subsidiary and took concrete steps toward commercializing regenerative cell medicine. - FY2023RaisedAnnual report
「To achieve non-linear growth, we will newly add the MR (Medical Robot) business and regenerative cell therapy business, among others, and promote initiatives to expand our business domains.」
The company has explicitly stated its policy of adding the MR business and regenerative cell therapy business to its existing IVD- and life sciences-centered portfolio and expanding its business domains. - FY2022Specified the key actions under the medium-term plan.Annual report
「The Group launched a new medium-term management plan in April 2021, covering the fiscal years ending March 2022 through March 2024. To achieve the positioning goals under the long-term vision toward 2025, established in 2018, we have set key actions to undertake over the next 3 years and will continue to promote the implementation of specific measures. In addition to hematology, the Group's largest source of revenue, we have designated blood coagulation testing, immunoassay and life sciences as priority areas, and will strengthen research and development through prioritized resource allocation to create new value and expand our product lineup. We will also continue efforts to create and develop new businesses centered on surgical support robots, with the aim of achieving non-linear growth.」
The new medium-term plan through the fiscal year ending March 2024 specifically sets out key actions for the next 3 years, priority resource allocation to 4 priority areas and the development of new businesses centered on surgical support robots. - FY2021AdvancedAnnual report
「Under the Group's medium-term management plan, we will strengthen research and development by prioritizing resource allocation to the hematology field, the Group's largest source of revenue, as well as the blood coagulation testing, immunoassay and life sciences fields, which have been designated as priority areas, in order to achieve our positioning goals under the long-term vision toward 2025, established in 2018, thereby creating new value and expanding our product lineup.」
The previous direction of existing core businesses and next-generation core businesses such as genetic testing has been developed into priority resource allocation for hematology, blood coagulation testing, immunoassay and life sciences as priority areas. - FY2020RestatedAnnual report
「We will strengthen growth and profitability by expanding our product lineup in hematology, urinalysis, blood coagulation testing and immunoassay, expanding our life sciences business and creating new diagnostic value that contributes to personalized medicine.」
The company has reiterated its direction for the business portfolio: strengthening existing core IVD fields and positioning life sciences and personalized medicine as the next growth areas. - FY2018RestatedAnnual report
「In addition to strengthening global growth potential and profitability in our core fields of hematology, blood coagulation testing, immunoassay and urinalysis, we have positioned fields such as genetic testing as next-generation core businesses and have pursued their commercialization through active investment.」
The company has reiterated its direction for the business portfolio: strengthening existing core businesses and actively investing in genetic testing and other fields as next-generation core businesses. - FY2017First statedAnnual report
「With a view to sustained growth from 2020 onward, we will accelerate the pace of execution, promote transformation of our business portfolio and invest in transformation initiatives, including human resources and IT infrastructure.」
The company has explicitly stated for the first time its plans to transform its business portfolio with a view to growth from 2020 onward and invest in human resources and IT infrastructure.